DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DVX-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DVX-201 overview
DVX-201 is under development for the treatment of myeloproliferative disorders, relapsed acute myeloid leukemia, refractory acute myeloid leukemia, myelodysplastic syndrome influenza, COVID-19 and respiratory syncytial virus (RSV). It is administered by the parenteral route. The drug candidate comprises of allogenic natural killer (NK) cells derived from pooled donor CD34 plus HSPCs.
Coeptis Therapeutics overview
Coeptis Therapeutics is a biopharmaceutical company that involved in the development, and commercialization of branded and generic pharmaceutical products and cell therapy platforms for patients with cancer. The company is headquartered in Wexford, Pennsylvania, the US.
For a complete picture of DVX-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
